With Third Quarter Results, Biogen Idec Continues to Ride Its Warhorse Avonex
This article was originally published in The Pink Sheet Daily
Executive Summary
Q3 results were strong, thanks to Avonex, but new competition from Novartis' oral MS therapy Gilenya and dwindling Rituxan royalties from Roche threaten longer-term outlook.
You may also be interested in...
Biogen Turns In Robust Quarter, Fueled By Avonex; Late-Stage Commercial Catalysts Abound
In the second quarter, Biogen demonstrated a continuing ability to milk revenue from established MS products while it prepares to launch a wave of potentially market-shifting NMEs.
Biogen/Elan Submit Applications For Tysabri Label Change Ahead of Schedule
In a bid to solidify Tysabri's place in an increasingly competitive market, Biogen/Elan push forward with changes to the multiple sclerosis medicine's label that help define the risk of a rare brain infection.
Biogen/Elan Submit Applications For Tysabri Label Change Ahead of Schedule
In a bid to solidify Tysabri's place in an increasingly competitive market, Biogen/Elan push forward with changes to the multiple sclerosis medicine's label that help define the risk of a rare brain infection.